Michael Gelband’s Recursion Pharmaceuticals RXRX Stock Holding History

Michael Gelband’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$913K	Sell	248,783 -97,967	-28%	-$326K	0.01%	1099
2026 Q1	$1.06M	Sell	346,750 -45,051	-11%	-$174K	0.01%	983
2025 Q4	$1.6M	Buy	391,801 +186,564	+91%	+$924K	0.01%	835
2025 Q3	$1M	Buy	205,237 +159,824	+352%	+$839K	0.01%	956
2025 Q2	$230K	Buy	+45,413	New	+$223K	﹤0.01%	1290
2024 Q2	–	Sell	-61,689	Closed	-$615K	–	1923
2024 Q1	$615K	Buy	+61,689	New	+$687K	﹤0.01%	1091
2023 Q2	–	Sell	-31,137	Closed	-$208K	–	2194
2023 Q1	$208K	Buy	+31,137	New	+$247K	﹤0.01%	1568
2022 Q4	–	Sell	-45,832	Closed	-$488K	–	2062
2022 Q3	$488K	Sell	45,832 -146,241	-76%	-$1.48M	0.01%	1379
2022 Q2	$1.56M	Buy	192,073 +158,360	+470%	+$1.06M	0.02%	893
2022 Q1	$241K	Buy	+33,713	New	+$358K	﹤0.01%	1842

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Michael Gelband's RXRX Position: Q2 2026 in Review

Michael Gelband reduced its Recursion Pharmaceuticals (RXRX) stake by 28% in Q2 2026, selling an estimated $326K and leaving 248,783 shares worth $913K. The position accounts for 0.01% of the portfolio, ranked #1099.

Michael Gelband first reported a position in RXRX in Q1 2022 and has held it in 10 quarters since. The position peaked at $1.6M in Q4 2025. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Michael Gelband held 248,783 shares of Recursion Pharmaceuticals worth $913K as of Q2 2026.
Michael Gelband sold 97,967 Recursion Pharmaceuticals shares in Q2 2026, an estimated $326K.
Recursion Pharmaceuticals made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1099 holding.
Michael Gelband first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
Michael Gelband's Recursion Pharmaceuticals position peaked at $1.6M in Q4 2025.
339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.